Literature DB >> 6378540

The lungs and causes of death in the nocturnal oxygen therapy trial.

J Jacques, T P Cooney, G W Silvers, T L Petty, J L Wright, W M Thurlbeck.   

Abstract

Autopsy findings and a morphometric study of the lungs were compared in 18 subjects receiving nocturnal oxygen and 15 receiving continuous oxygen in the National Heart, Lung, and Blood Institute Nocturnal Oxygen Therapy Trial (about half of those who died). The emphysema score, average interalveolar wall distance, central airway lesions, peripheral airway lesions, and the ratio of weights of left ventricle plus septum to right ventricle were similar in the two groups. The causes of death in the two groups were also similar. This evidence supports the hypothesis that the improved prognosis observed with continuous oxygen therapy nocturnal oxygen therapy in patients with severe chronic airflow obstruction and hypoxemia was due to treatment. There was a trend for there to be more interstitial fibrosis and type 2 alveolar epithelial cell hyperplasia in those treated with nocturnal oxygen; in the hands of one observer, the type 2 cell hyperplasia was significant.

Entities:  

Mesh:

Year:  1984        PMID: 6378540     DOI: 10.1378/chest.86.2.230

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Clinicopathological correlations in cor pulmonale.

Authors:  P M Calverley; R Howatson; D C Flenley; D Lamb
Journal:  Thorax       Date:  1992-07       Impact factor: 9.139

2.  Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.

Authors:  Aboelyazid Elkilany; Dominik Geisel; Tobias Müller; Andreas Fischer; Timm Denecke
Journal:  Abdom Radiol (NY)       Date:  2020-09-12

Review 3.  ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour.

Authors:  Peter M A Calverley; Paul Phillip Walker
Journal:  Diagnostics (Basel)       Date:  2021-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.